| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Alaunos Therapeutics, Inc.
13D/A
Amendment 4
TCRT · 98973P309
|
8.6% |
3/5/2026
Event 2/24/2026
|
|||
| Price Adrian | 8.6% | ||||
| Chris Butterworth | 0.5% | ||||
| Richard Jones | 0.7% | ||||
| Edward Jones | 0.5% | ||||
| Gareth Downing | 0.9% | ||||
| Richard Kotey | 0.6% | ||||
| Chris Cole | 0.7% | ||||
| Arif Chaudrey | 0.3% | ||||
| Emma Babb | 0.5% | ||||
| Colin Craig | 0.3% | ||||
| John Nicholls | 0.8% | ||||
| Carl Ware | 0.1% | ||||
| Andrew Turner | 0.6% | ||||
| Matthew Robbins | 0.5% | ||||
| Phillip James Stead | 0.5% | ||||
| Stephen Hennessy | 0.3% | ||||
| Greg Arnold | 0.5% | ||||
| Michelle Douglas | 0.4% | ||||
| HexagonONE Ltd | 0% | ||||
| Alimenta Holding Limited | 0% | ||||
| Krakatau Holding Limited | 0% | ||||
|
Alaunos Therapeutics, Inc.
13D/A
Amendment 3
TCRT · 98973P309
|
8.6% |
2/24/2026
Event 2/24/2026
|
|||
| Price Adrian | 8.6% | ||||
| Chris Butterworth | 0.5% | ||||
| Richard Jones | 0.7% | ||||
| Edward Jones | 0.5% | ||||
| Gareth Downing | 0.9% | ||||
| Richard Kotey | 0.6% | ||||
| Chris Cole | 0.7% | ||||
| Arif Chaudrey | 0.3% | ||||
| Emma Babb | 0.5% | ||||
| Colin Craig | 0.3% | ||||
| John Nicholls | 0.8% | ||||
| Carl Ware | 0.1% | ||||
| Andrew Turner | 0.6% | ||||
| Matthew Robbins | 0.5% | ||||
| Phillip James Stead | 0.5% | ||||
| Stephen Hennessy | 0.3% | ||||
| Greg Arnold | 0.5% | ||||
| Michelle Douglas | 0.4% | ||||
| Hexagon ONE Inc | 0% | ||||
| Alimenta Holding Inc | 0% | ||||
| Krakatau Holding Inc | 0% | ||||
|
Alaunos Therapeutics, Inc.
13D/A
Amendment 2
TCRT · 98973P309
|
8.6% |
12/5/2025
Event 10/30/2025
|
|||
| Price Adrian | 8.6% | ||||
| Chris Butterworth | 0.5% | ||||
| Richard Jones | 0.7% | ||||
| Edward Jones | 0.5% | ||||
| Gareth Downing | 0.9% | ||||
| Richard Kotey | 0.6% | ||||
| Chris Cole | 0.7% | ||||
| Arif Chaudrey | 0.3% | ||||
| Emma Babb | 0.5% | ||||
| Colin Craig | 0.3% | ||||
| John Nicholls | 0.8% | ||||
| Carl Ware | 0.1% | ||||
| Andrew Turner | 0.6% | ||||
| Matthew Robbins | 0.5% | ||||
| Phillip James Stead | 0.5% | ||||
| Stephen Hennessy | 0.3% | ||||
| Greg Arnold | 0.5% | ||||
| Michelle Douglas | 0.4% | ||||
|
Alaunos Therapeutics, Inc.
13D/A
Amendment 1
TCRT · 98973P309
|
8.6% |
10/31/2025
Event 10/30/2025
|
|||
| Chris Butterworth | 0.5% | ||||
| Richard Jones | 0.7% | ||||
| Edward Jones | 0.5% | ||||
| Gareth Downing | 0.9% | ||||
| Richard Kotey | 0.6% | ||||
| Chris Cole | 0.7% | ||||
| Arif Chaudrey | 0.3% | ||||
| Emma Babb | 0.5% | ||||
| Colin Craig | 0.3% | ||||
| John Nicholls | 0.8% | ||||
| Carl Ware | 0.1% | ||||
| Andrew Turner | 0.6% | ||||
| Matthew Robbins | 0.5% | ||||
| Phillip James Stead | 0.5% | ||||
| Stephen Hennessy | 0.3% | ||||
| Greg Arnold | 0.5% | ||||
| Michelle Douglas | 0.4% | ||||
| Price Adrian | 8.6% | ||||
|
Alaunos Therapeutics, Inc.
13D
TCRT · 98973P309
|
8.6% |
10/30/2025
Event 10/30/2025
|
|||
| Chris Butterworth | 0.5% | ||||
| Richard Jones | 0.7% | ||||
| Edward Jones | 0.5% | ||||
| Gareth Downing | 0.9% | ||||
| Richard Kotey | 0.6% | ||||
| Chris Cole | 0.7% | ||||
| Arif Chaudrey | 0.3% | ||||
| Emma Babb | 0.5% | ||||
| Colin Craig | 0.3% | ||||
| John Nicholls | 0.8% | ||||
| Carl Ware | 0.1% | ||||
| Andrew Turner | 0.6% | ||||
| Matthew Robbins | 0.5% | ||||
| Phillip James Stead | 0.5% | ||||
| Stephen Hennessy | 0.3% | ||||
| Greg Arnold | 0.5% | ||||
| Michelle Douglas | 0.4% | ||||
| Price Adrian | 8.6% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.